Skip to content
Life Sciences Series B Founded 2008

BioLamina

BioLamina manufactures full-length human recombinant laminins for primary and stem-cell culture applications. The company's product portfolio includes recombinant laminins as cell culture matrices for pluripotent stem cell culture, early epithelial development, differentiation, and screening kits. Founded in 2008 and headquartered in Sundbyberg, Sweden, BioLamina has raised approximately $18.2M in Series B funding…

📍 Sundbyberg, Sweden · Life Sciences Platforms and Tools,

Funding snapshot

Last roundSeries B
Amount$24M
Date17 April 2026
Total raised$18M
Team size119

About

BioLamina manufactures full-length human recombinant laminins for primary and stem-cell culture applications. The company's product portfolio includes recombinant laminins as cell culture matrices for pluripotent stem cell culture, early epithelial development, differentiation, and screening kits. Founded in 2008 and headquartered in Sundbyberg, Sweden, BioLamina has raised approximately $18.2M in Series B funding from investors including Lauxera Capital Partners, Bure Equity, Northislet, and the European Investment Bank. The company's laminin-based matrices provide biologically relevant substrates that mimic the natural extracellular environment, enabling researchers to culture cells with improved consistency and physiological relevance for regenerative medicine, drug discovery, and cell therapy development.

Business model

Genomics > Enabling Technologies > Kits and Reagents > Bioreagents,

Life Sciences Platforms and Tools > Research Reagents and Kits > Diversified

Institutional investors

Lauxera Capital Partners Bure Equity Northislet Europa HHS European Investment Bank Nxt2b

Latest coverage

No articles yet.

Raising like BioLamina?

Analyze your pitch deck before your next raise.

Analyze My Deck →